Future Aspects for Cannabinoids in Breast Cancer Therapy

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Cannabinoids (CBs) from Cannabis sativa offer palliative care for cancer symptoms like nausea, anorexia, and pain.
• CBs, including delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), demonstrate potential in decelerating tumor progression, particularly in breast cancer models.

Purpose of the Study:

• To explore the mechanisms by which CBs affect cancer cell signaling pathways.
• To evaluate the efficacy of CBs in various breast cancer subtypes and stages.

Main Methods:

• Investigated the interaction of CBs with G-protein coupled cannabinoid receptors (CB-Rs) like CB1-R and CB2-R.
• Analyzed the effects of CBs on cancer cell proliferation, apoptosis, angiogenesis, and metastasis in preclinical models.
• Examined the influence of CBs on signaling pathways such as extracellular-signal-regulated kinase and protein kinase B.

Main Results:

• CBs, particularly THC and CBD, inhibited disease progression in breast cancer models.
• CB2-R expression is linked to tumor aggressiveness in breast cancer.
• CBs demonstrated anti-cancer effects across estrogen receptor-positive, estrogen-resistant, HER2-positive, and triple-negative breast cancer cells.
• CBs reduced angiogenesis and metastasis in animal models and blocked cell cycle progression.

Conclusions:

• Cannabinoids show promise in decelerating tumor progression and metastasis in breast cancer.
• CBs may be effective in both advanced and earlier stages of breast cancer treatment.
• Further research into CBs' role in cancer therapy is warranted.